N/A
Completed N=30
Early Interventional Treatment for Cancer Pain
Source: ClinicalTrials.gov NCT05366413 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcomePrimary: Feasibility - Pain Consultation — 29 Participants
Summary
The purpose of the study is to evaluate how feasible and beneficial it is to refer patients with cancer pain to a doctor who specializes in pain management, including procedures to relieve pain, and whether this is helpful to patients with pain related to their cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility - Pain Consultation |
29 | — |
| PRIMARY Feasibility - Interventional Pain Procedure Rate |
18 | — |
| PRIMARY Acceptability - Satisfaction Ratings |
15 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of a metastatic, or locally advanced unresectable malignancy
- Anticipated prognosis of more than 6 months according to the primary oncologist
- Age greater than 21 years
- Persistent pain with an average pain rating of 4 or greater on an 11-point numeric rating scale (NRS) from 0-10 where 10 is considered the most severe.
- Pain has persisted for at least 2 weeks
- Pain is due to cancer or sequelae of cancer treatment
Exclusion Criteria
- Primary pain syndrome is sensory peripheral neuropathy
- Patient is taking more than 200 morphine milligram equivalents (MMEs) per day on average, at the time of recruitment.
- Currently cared for by interventional pain management specialist
- Receipt of prior pain intervention (e.g. celiac neurolysis)
- Bleeding diathesis, uncontrollable infection, or other contra-indications to pain interventions
- History of opioid misuse disorder
- Inability to speak English
- Cognitive impairment or any other disorder that would impede study participation and survey completion
- If patients are unable to complete the baseline survey, they will no longer be considered eligible for the study; this will serve as an indication of barriers to participation that would make them unable to comply with study procedures.
Data sourced from ClinicalTrials.gov (NCT05366413). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.